source
- Oculis’ eye drops for diabetic macular edema flunk Phase 3 testOculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS-0…Endpoints · 2mo ago↗ source
- STAT+: A standing ovation for RevMed, and caution for AkesoASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.STAT · 2mo ago↗ source
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.STAT · 2mo ago↗ source